Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Vaccines
PharmAthene Submits Response to DHHS Request for Proposals for SparVax(TM) - a Recombinant Protective Antigen Vaccine
August 13th, 2008
PharmAthene, Inc. (AMEX:PIP) a biodefense company specializing in the development and commercialization of medical countermeasures against chemical and biological threats, announced that it has submitted a response to a Request for Proposals for an Anthrax Recombinant Protective Antigen (rPA) Vaccine for the Strategic National Stockpile (Solicitation Number: RFP BARDA 08-15) for SparVax(TM), the Company's novel rPA anthrax vaccine. On February 28, 2008, the Department of Health and Human Services (DHHS) issued a formal solicitation, referred to as a Request for Proposals, for an Anthrax Recombinant Protective Antigen Vaccine for the Strategic National Stockpile. The...
Source: Vaccine Weekly (2008-08-13)
|
